QLS2401 / Qilu Pharma - LARVOL DELTA

QLS2401: A novel PSMA/STEAP1/CD3 tri-specific T-cell engager for the treatment of mCRPC (AACR 2026) - "QLS2401 was well-tolerated in a toxicity study in cynomolgus monkeys, with an HNSTD (Highest Non-Severely Toxic Dose) significantly higher than that of the xaluritamig analog. In conclusion, preclinical studies have demonstrated that QLS2401 exhibits an expanded therapeutic window, superior efficacy and improved tolerability compared to the xaluritamig analog."

Trispecific • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • STEAP1